REG - OptiBiotix Health - Directorate Change

OptiBiotix HealthAnnouncement

28/08/2019 07:05

RNS Number : 3219K
OptiBiotix Health PLC
28 August 2019
 


28 August 2019
OptiBiotix Health plc
("OptiBiotix" or the "Company")
 
Directorate Change
 
OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, cardiovascular disease and diabetes, announces the departure of Christina Wood as Executive Sales & Marketing Director by mutual agreement. Dr Fred Narbel, Managing Director of OptiBiotix's prebiotic division containing its SweetBiotix, OptiBiotic and microbiome modulating technology platforms will take over Christina's responsibilities for SlimBiome and GoFigure.
 
OptiBiotix will continue to evolve the executive and non-executive team in-line with the changing needs of the business with the aim of delivering profitable divisions across all areas of the Company.
 
Stephen O'Hara, CEO of OptiBiotix, commented: "On behalf of the Board, I would like to thank Christina for her professionalism and hard work with OptiBiotix and wish her all the best in the future". 
 
 
This announcement contains information which, prior to its disclosure, was considered inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 (MAR).
 
For further information, please contact:
 



OptiBiotix Health plc


www.optibiotix.com




Stephen O'Hara, Chief Executive


Contact via Walbrook below














Cairn Financial Advisers LLP (NOMAD)








Liam Murray / Jo Turner / Ludovico Lazzaretti


Tel: 020 7213 0880














finnCap (Broker)








Geoff Nash / Kate Bannatyne (Corporate Finance)


Tel: 020 7220 0500




Camille Gochez (Corporate Broking)


















goetzpartners securities Limited


Tel: 0203 859 7725




Ulrich Kinzel 


















Walbrook PR Ltd








Anna Dunphy


Mob: 07876 741 001









 
 
 
 
Caution regarding forward looking statements
Certain statements in this announcement, are, or may be deemed to be, forward looking statements. Forward looking statements are identified by their use of terms and phrases such as ''believe'', ''could'', "should" ''envisage'', ''estimate'', ''intend'', ''may'', ''plan'', ''potentially'', "expect", ''will'' or the negative of those, variations or comparable expressions, including references to assumptions. These forward looking statements are not based on historical facts but rather on the Directors' current expectations and assumptions regarding the Company's future growth, results of operations, performance, future capital and other expenditures (including the amount, nature and sources of funding thereof), competitive advantages, business prospects and opportunities. Such forward looking statements reflect the Directors' current beliefs and assumptions and are based on information currently available to the Directors.
 
 
 
About OptiBiotix - www.optibiotix.com 
OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness. 
 
OptiBiotix has an extensive R&D program working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.
 
OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes. 
 




This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
BOAQDLFLKVFXBBB